

**TABLE 2. EFFECT SIZES IN DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS OF PHARMACOTHERAPY FOR PTSD<sup>A</sup>**

	Drug				Placebo		Drug vs Placebo	
	N studies	n	% Change <sup>b</sup>	Effect Size Mean (SD)	n	% Change <sup>b</sup>	Effect Size Mean (SD)	Effect Size Mean (SD)
<b>Sertraline<sup>1</sup></b>	5	471	36	1.54 (0.69)	474	29	1.30 (0.63)	0.31 (0.20)
<b>Fluoxetine<sup>2</sup></b>	5	464	44	2.35 (0.38) <sup>c</sup>	245	32	1.83 (0.39) <sup>c</sup>	0.62 (0.37) <sup>d</sup>
<b>Paroxetine<sup>3</sup></b>	3	541	44	1.77 (0.69)	363	30	1.22 (0.41)	0.57 (0.31)
<b>Venlafaxine<sup>4</sup></b>	2	340	57	3.16 (0.54)	347	48	2.61 (0.40)	0.48 (0.04)
<b>Mirtazapine<sup>5</sup></b>	1	17	35	1.06 (--)	9	17	0.86 (--)	0.60 (--)
<b>Risperidone augmentation<sup>6</sup></b>	4	67	26	0.99 (0.60)	63	21	0.87 (0.44)	0.26 (0.53)
<b>Olanzapine augmentation<sup>7</sup></b>	1	10	17	0.67 (--)	9	3	0.16 (--)	0.75 (--)

<sup>a</sup> Effect sizes calculated from the raw data reported in the articles. Within group effect sizes calculated as mean change score divided by the standard deviation of the baseline score. Between-groups effect sizes were calculated as mean change score between drug and pill placebo groups divided by standard deviation of the baseline score for placebo group.

<sup>b</sup> Percent reductions in PTSD symptoms pre- to post-treatment

<sup>c</sup> Within treatment effect sizes for one study (van der Kolk et al, 1994) were not available and thus excluded.

<sup>d</sup> Drug vs placebo effect size for one study (van der Kolk et al, 1994) taken from [127]

1 = [128-132], 2 = [125, 133-136], 3 = [137-139], 4 = [132, 140], 5 = [141], 6 = [142-145], 7 = [146]